Navigation Links
Seroquel to Treat Depression In Case Of Bipolar Disorder

AstraZeneca the Head of the Anglo-Swedish Company has come out with the results of the drug Seroquel stating that it be used in the treatment of // both maniac behaviour and mental depression in people suffering with bipolar disorders.

He has asked US to consider his drug as a sole treatment for maniac and depression symptoms related to bipolar disorder.

AstraZeneca, the drug czar has requested the number of drug regulators spread across the Atlantic to approve Seroquel.

Previously the drug was given permission to be used in the treatment of mania.

But now with his research and other works done at the base in Alderley Edge he has supplied new information based on clinical trail that it is very effective in treating patients suffering from mental depression.

Bipolar disorder is a characteristic mental imbalance in which the individual experience severe mood swings and also feels euphoric during episodes of mania and then immediately suffers from the lows characteristic of mental depression.

The incidence of this disease is very low and is about 3-4 % among the adults. It is the sixth leading cause of disability in the world.

Doctors say that the condition might be associated with genes and may be hereditary. It affects equal number of patients in both the sexes.

The acquiescence of the license for the new drug from the US Food and Drug Administration (FDA) would be an important milestone in the history of the drug.

The drug Seroquel alone spawned a profit of 1.16 billion pounds in 2004.


'"/>




Page: 1

Related medicine news :

1. Astra Zenecas Seroquel Gets FDA Approval For Schizophrenia
2. Advances in Treatment of Cataracts
3. Recommendations for Treatment of Blood Pressue
4. New FDA Approved Drug To Treat Migraine
5. Treatment for Menieres disease
6. Treatment for pre-menstrual syndrome is ineffective
7. Angiotensin-II-receptor blockers - Treat kidney failure
8. Cipro Has Cheaper Cousins to Treat Anthrax
9. Better Treatment for obesity
10. Gene Treatment for Heart Disease
11. Cyclosporin A Treats Leukemia Complications
Post Your Comments:
(Date:9/5/2008)... HARRISBURG, Pa., Sept. 5 /PRNewswire-USNewswir...day issued a proclamation acknowledging Sept. 11 a...wealth of Pennsylvania and The American Red Cross ...memoration of those who lost their,lives on 9/11 a...e blood,donation can save up to three lives., "We...
(Date:9/5/2008)...Researchers explain how theoretical ,anti-cloak, c...DAY, Sept. 5 (HealthDay News) -- Just in case some...inese scientists say they know how to uncloak the ...hed in Optics Express , certain materials underne...jects to be seen again. , Researchers at Shangh...
(Date:9/5/2008)... FRANKLIN, Mass., Sept. 5 /PRNewswire/ -- Arthr...he developer of less-invasive joint,resurfacing sy...m the U.S.,FDA to begin its pivotal investigation ...he FDA stated that "there are no outstanding safet...initiation., Arthrosurface has been evaluating th...
(Date:9/5/2008)... WHITE PLAINS, N.Y., Sept. 5 /PRNewswire/ -- To...elevision networks, entertainment industry,executi...esearch and,patient advocacy join forces to Stand ...hour simulcast from 8:00 p.m. to 9:00 p.m. ET on t... unprecedented platform to elevate,the discussion ...
Breaking Medicine News(10 mins):Health News:Arthrosurface HemiCAP(R) Focal Knee Resurfacing Implant Receives FDA Approval to Move into Final Investigational Stage 2Health News:The Leukemia & Lymphoma Society: Standing Up to Cancer for 60 Years 2
...rs have identified a key receptor that could be a ...f acute respiratory distress syndrome (ARDS). //Th...tening condition. The receptor is similar to wha... taste (G-protein coupled receptors) There is no e...
...e Prime Minister Mr. Man Mohan Singh to take the i...he films and television. // With the ministries of...o reach consensus on modalities for implementing t...ter approached Prime Minister Manmohan Singh to re...
...be able to isolates molecule that would be helpful...volutionary study has been done independently by t...spital Boston and they have identified a master pr...change as a result of individual experiences. Sci...
...rnment on Wednesday for neglecting their duties ac... of Bihar Mr. Nitish Kumar gave the nod for the di...ried out with immediate effect. Last week, the go...edical officers and initiated departmental proceed...
Other Medicine News:
(Date:9/3/2008)... that Multaq(R) (dronedarone) decreased the risk o...n or atrial flutter already adequatel... N.J., Sept. 3 /- The resul...ENA study were presented today at,the clinical tri...ology,congress 2008, in Munich, Germany. Previous ...
(Date:9/3/2008)...erations, Updates Zingo Launch Progress and Adlea ... Conference Call Today at 11:30 am ET,...-FirstCall/ -- Anesiva,Inc. (Nasdaq: ANSV ) anno...ations to focus on commercial and late-stage produ...pecialty pharmaceutical pain management,company. T...
(Date:9/3/2008)...uated in Repeat-Dosing Study in Subjects with ALS,... -- Sangamo,BioSciences, Inc. (Nasdaq: SGMO ) ann... trial (SB-509-801) to evaluate its drug, SB-509, ...motor-neuron disease for which there,are limited t...-509, is an injectable formulation of a plasmid,en...
(Date:9/2/2008).../- Forest Laboratories, Inc...day announced results from,two global Phase III st...nhaled anticholinergic for the treatment of patien...D). In both the ACCLAIM/COPD I&II,(AClidinium CLin...te to,Severe COPD Patients) studies, once-daily ac...
Breaking Medicine Technology:Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 2Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 3Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 4Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 5Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 2Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 3Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 4Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 5Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 2Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 3Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 4Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 5Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 2Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 3Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 4Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 5Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 6Gerber Scientific to Present at 10th Annual Needham Growth Stock Conference 9000 1Gerber Scientific to Present at 10th Annual Needham Growth Stock Conference 9000 2Transcript of Elizabeth Mazzocchi Press Conference 8996 1Transcript of Elizabeth Mazzocchi Press Conference 8996 2Transcript of Elizabeth Mazzocchi Press Conference 8996 3Transcript of Elizabeth Mazzocchi Press Conference 8996 4Transcript of Elizabeth Mazzocchi Press Conference 8996 5Exelixis Announces January 10 Webcast of Presentation at the 26th Annual JPMorgan Healthcare Conference 2415 1Oncolytics Biotech Inc Announces Filing of Phase 1 2 Clinical Trial with REOLYSIN 28R 29 2411 1Oncolytics Biotech Inc Announces Filing of Phase 1 2 Clinical Trial with REOLYSIN 28R 29 2411 2
...Donnelly, MT (ASCP) Contributing Editor , ,Qu...y to meeting the needs of doctors and patients by ...hods. Vendors of these systems can be a valuable r...tocols to help lab managers ensure that analytical...oping suitable QC materials for today,s laboratori...
...l S. Singer, M.D., Ph.D. Contributing Editor Harva...l for heart failure in African American patients h...espond differently to the same medication. This c...edications, and in many cases is due to individual...ics focuses on these issues, valuable new laborato...
Other Medicine Technology:New Quality Control Systems for Every Laboratory Application 2New Quality Control Systems for Every Laboratory Application 3Gene Chips to Detect CYP Variations: A New Step Toward Customized Medical Therapy. 2Gene Chips to Detect CYP Variations: A New Step Toward Customized Medical Therapy. 3
The OCULUS Pachycam is the first compact and portable non-contact pachymeter with built-in keratometer. The OCULUS Pachycam has automatic correction of the IOP (intra ocular pressure) in accordance
...ologies - plus wavefront analysis - in one easy-to...a single device, you can obtain refraction, cornea...vefront analysis. The 3-D Wave allows you to evalu...ve and cataract surgery screenings, evaluate posto...
...re sensor and continues to lead the way. PressureW...measures pressure, temperature and flow. With sign..., it also serves as your primary guidewire, as wel...gh-performance guidewire. , Intracoronary pressu...
...nd and MRI-guided vacuum assisted breast biopsies ...d, FDA-cleared ATEC system for a faster, safer, ea... biopsy. Its compassionate care at its best for th...eful for biopsy and diagnostic excision of breast ...
Medicine Products: